Understanding complex biology through AI

We integrate the best of human and artificial intelligence to deliver better drugs and diagnostics at scale

Understanding complex biology through AI

We integrate the best of human and artificial intelligence to deliver better drugs and diagnostics at scale

We are the first end-to-end AI biotech

By understanding complex biology through cutting-edge AI, we identify new treatments, de-risk and accelerate clinical trials, and build diagnostic tools to reduce time to impact for patients.

Multimodal patient data

Owkin works with top academic centers to curate, enrich and generate deep, multimodal data that is AI ready.

Federated research network MOSAIC

AI-biomarker discovery

We apply AI to multimodal, KOL-curated data to subtype patients and identify novel biomarkers to inform drug discovery, de-risk clinical trials and develop and deploy diagnostics in clinical practice.

Subgroup discovery

AI drug discovery

We use AI to identify biomarkers from patient biology, match patient subpopulation with candidate target, and match drugs with new indications or subpopulations of existing indications.

BiomarkerPLUS TargetMATCH DrugMATCH

AI drug development

We combine machine learning methodologies, patient data, and innovative modalities to increase the probability of success of clinical trials.

AI external control arms Inclusion criteria models Covariate adjustment

AI diagnostics

Our AI Dx help pre-screen for biomarkers, and predict outcomes — giving pharma companies, researchers and oncologists a fuller picture of a patient’s disease. This means more patients can benefit from targeted therapies.

MSIntuit® CRC RlapsRisk® BC TLS-Detect CDx

What makes Owkin different?

Owkin is differentiated by a focus on improving our fundamental understanding of disease mechanics through data, biology and AI.

Unparalleled access to multimodal data

Leverage our network of leading academic partners and medical experts to access world-class patient data, through privacy-enhancing technologies
Research-grade, multimodal data to capture the full heterogeneity of disease
Cutting-edge new modalities such as single-cell and spatial omics via MOSAIC

Federated research network

Cutting-edge AI

Interpretable predictive models validated by medical experts
Multiscale AI to connect the dots across cellular, molecular, and tissue scales, capturing the causal links of complex biology
State-of-the-art AI, such as large language models (LLMs), AI-agents and foundation models (FMs) to further increase the performance of our models

Drug discovery approach

Grounded in biology

Experimentally validate AI-derived subgroups and candidate drug targets
Our lab-in-the-loop integrates wet lab data and AI to create a powerful feedback loop that accelerates our R&D
We use insights from multimodal patient data to guide and inform our research to understand cancer and tumor microenvironment interactions

Our scientific publications

What makes our pipeline different?

Powered by multimodal patient data, our AI models match novel targets with patient subgroups to identify the best treatments.

We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation.

View our pipeline

Discover our groundbreaking science

Press release

Owkin announces first patient dosed in Phase 1 Clinical Trial of OKN4395, a first-in-class EP2/EP4/DP1 triple inhibitor for patients with solid tumors

January 30, 2025

Press release

Owkin announces first patient dosed in Phase 1 Clinical Trial of OKN4395, a first-in-class EP2/EP4/DP1 triple inhibitor for patients with solid tumors

January 30, 2025

Press release

Owkin announces Owkin K1.0 Turbigo, a cutting-edge operating system to create the first AGI for biology, at JP Morgan Healthcare Conference

January 13, 2025

Press release

Owkin announces Owkin K1.0 Turbigo, a cutting-edge operating system to create the first AGI for biology, at JP Morgan Healthcare Conference

January 13, 2025

Conference

AUTM 2025

Partnership opportunities and how we work with top academic centers to curate, enrich and generate deep, multimodal data.

March 2, 2025

Case study

Case study: Stratification biomarker

Biomarker of response to immunotheraphy in NSCLC

We are hiring

Join our team

We are a community of diverse people bringing our energy and skills to find the right treatment for every patient.

Careers at Owkin

“Thanks to the solution we now have a better understanding of the underlying mechanism of highly aggressive tumors and the treatment needs for these patients. Identifying very high-risk patients earlier will enable us to adjust the therapeutic strategy for more favorable patient outcomes.”

Pr Fabrice Andre

Director of Research (Gustave Roussy) ESMO president

"I'm excited about the Sanofi and Owkin collaboration and its potential to transform drug discovery. Owkin's data network and AI capabilities, combined with Sanofi's expertise, can potentially lead to new treatments and better patient outcomes."

Frank Nestle, MD

Global Head of Research and Chief Scientific Officer, Sanofi

"AI has the potential to significantly enhance the way that patients are treated and Owkin is at the forefront of this exciting field."

Professor Miriam Merad, MD, PhD

Director of the Precision Immunology Institute, Mount Sinai School of Medicine

"The application of AI technologies holds tremendous potential in the screening of patients and the diagnosis of disease. We look forward to working with the Owkin team toward harnessing this opportunity to identify more patients with MSI-H cancers who may benefit from ICI therapy."

Scott K. Pruitt, MD, PhD

Associate Vice President & Head, Translational Oncology, MSD Research Laboratories

Pr Fabrice Andre

Director of Research (Gustave Roussy) ESMO president